Morpholino

MO3-pla2g4aa

ID

ZDB-MRPHLNO-160426-1

Name

MO3-pla2g4aa

Previous Names

ATG (1)

Target

pla2g4aa (1)

Sequence

5' - AGGTCAGGATGGCACCTTATTTCAA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

Translation-blocking MO.

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO3-pla2g4aa

Expressed Gene	Anatomy	Figures
stm	otic vesicle	Fig. 4 from Naini et al., 2016

Phenotype

Phenotype resulting from MO3-pla2g4aa

Phenotype	Fish	Figures
otic vesicle decreased size, abnormal	WT + MO3-pla2g4aa	Fig. 4 from Naini et al., 2016

Phenotype of all Fish created by or utilizing MO3-pla2g4aa

Phenotype	Fish	Conditions	Figures
otic vesicle decreased size, abnormal	WT + MO3-pla2g4aa	standard conditions	Fig. 4 from Naini et al., 2016
head size, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: prostaglandin E2	Fig. 4 from Naini et al., 2016
cell cycle G1/S phase transition decreased process quality, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	standard conditions	Fig. 5 from Naini et al., 2016
otolith incomplete structure, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
cell cycle G1/S phase transition process quality, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: prostaglandin E2	Fig. 5 from Naini et al., 2016
extension decreased length, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
whole organism anterior-posterior axis length, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: prostaglandin E2	Fig. 4 from Naini et al., 2016
otolith decreased size, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
cell cycle G1/S phase transition process quality, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: arachidonic acid	Fig. 5 from Naini et al., 2016
cell cycle G1/S phase transition disrupted, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	standard conditions	Fig. 5 from Naini et al., 2016
whole organism anterior-posterior axis length, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: arachidonic acid	Fig. 4 from Naini et al., 2016
whole organism anterior-posterior axis decreased length, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
head decreased size, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
head size, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: arachidonic acid	Fig. 4 from Naini et al., 2016

Citations